Industry

Why the weight-loss drugs battle will intensify in 2026, explained in 5 charts

January 18, 2026

Plain Facts Why the weight-loss drugs battle will intensify in 2026, explained in 5 charts howindialives. com 6 min read 18 Jan 2026, 07:00 am IST Novo Nordisk executives project that oral pills could capture more than a third of the total obesity drug market by 2030. Photo: Reuters Summary Novo Nordisk and Eli Lilly have dominated the market until now, but this year is set to bring oral drugs, generics, and a fight for global dominance. Gift this article This is a Mint Premium article gifted to you.

Credit: Livemint

Key Highlights

Subscribe to enjoy similar stories.
Subscribe now Earlier this month Danish drugmaker Novo Nordisk launched its oral Wegovy weight-loss pill in the US, for "needle-averse patients".
The starting dose is priced at $149 a month for patients paying in cash, compared to the injectable version's list price of more than $1,300.
Novo executives project that oral pills could capture more than a third of the total obesity drug market by 2030.
Its rival Eli Lilly is expected to receive approval from the US Federal Drug Administration (FDA) for its own oral weight-loss drug, Orforglipron, by March 2026.

Sources

Why the weight-loss drugs battle will intensify in 2026, explained in 5 charts

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.